Current Report Filing (8-k)
February 04 2021 - 5:01PM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date
of Report (Date of earliest event reported): February 1, 2021
ADVAXIS, INC.
|
(Exact name of registrant as specified in its charter)
|
Delaware
|
|
001-36138
|
|
02-0563870
|
(State or other jurisdiction
of incorporation)
|
|
(Commission
File Number)
|
|
(IRS Employer
Identification No.)
|
305
College Road East
Princeton,
New Jersey
|
|
08540
|
(Address
of principal executive offices)
|
|
(Zip
Code)
|
Registrant’s
telephone number, including area code: (609) 452-9813
|
(Former
name or former address, if changed since last report.)
|
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant
under any of the following provisions (see General Instruction A.2. below):
[ ]
|
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
|
[ ]
|
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
|
[ ]
|
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
|
[ ]
|
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Securities
registered pursuant to Section 12(b) of the Act:
Title
of each class
|
|
Trading
Symbol(s)
|
|
Name
of each exchange on which registered
|
Common
stock, par value $0.001 per share
|
|
ADXS
|
|
Nasdaq
Capital Market
|
Preferred
Stock Purchase Right
|
|
-
|
|
Nasdaq
Capital Market
|
Indicate
by check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act
of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging
growth company [ ]
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period
for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. [ ]
On
February 1, 2021, Advaxis, Inc. (the “Company”) entered into a Consulting Agreement (the “Agreement”)
with GoalAssist Corporation (“Consultant”). The sole person responsible for Consultant’s performance under the
Agreement is Jerald Hammann.
Pursuant
to the Agreement, Consultant will serve as an independent contractor and will perform reasonable consulting services regarding
the Company’s business strategy, plans, goals and objectives, as requested by the Company’s Board of Directors, for
a term beginning on February 1, 2021 and ending on the close of business on January 31, 2022 (the “Term”). Additionally,
as requested by the Company during the Term, the Consultant may assist in facilitating the recruitment of research sites for the
Company, accelerating enrollment of study participants in the Company’s clinical trials and identifying opportunities for
cost savings.
For
consulting services rendered under the Agreement, Consultant will be entitled to receive a retainer amount of $150,000, payable
in four equal installments over the Term. Consultant will be entitled to receive additional fees upon the successful initiation
of a new clinical trial site, acceleration of certain clinical trial activities or the identification and implementation of cost
savings, in each case, which are the direct result of the Consultant’s efforts.
Under
the terms of the Agreement, the Consultant has agreed to customary confidentiality provisions, as well as restrictions on his
activities with respect to the Company, including restrictions on his ability to submit any director nominations or stockholder
proposals to the Company, or otherwise attempt in any way to influence the Company, through December 31, 2021.
SIGNATURE
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf
by the undersigned hereunto duly authorized.
February
4, 2021
|
ADVAXIS,
INC.
|
|
|
|
By:
|
/s/
Kenneth A. Berlin
|
|
Name:
|
Kenneth
A. Berlin
|
|
Title:
|
Chief
Executive Officer
|
Ayala Pharmaceuticals (QX) (USOTC:ADXS)
Historical Stock Chart
From Mar 2024 to Apr 2024
Ayala Pharmaceuticals (QX) (USOTC:ADXS)
Historical Stock Chart
From Apr 2023 to Apr 2024